Morrow Sodali will act as Information Agent in the Pfizer - Medivation M&A deal.
The Companies have entered into a definitive merger agreement under which Pfizer will acquire Medivation, a biopharmaceutical company focused on developing and commercializing small molecules for oncology, for $81.50 a share in cash for a total enterprise value of approximately $14 billion.
Related News
Elly Williamson named in Women in PR's 40 Over 40 Powerlist
24 June 2025
Shareholder activism: the reality of an escalating threat in Spain
08 June 2025
Sodali & Co improves ranking across the board as UK Financial PR adviser to FTSE companies
03 June 2025
Hayden Mattiske Joins Judging Panel for the 75th Australasian Reporting Awards
05 May 2025
Media enquiries
To contact our global experts for comments please get in touch below.
Contact us chevron_right